Aptevo Therapeutics (APVO) stock price, revenue, and financials

Aptevo Therapeutics market cap is $182.8 m, and annual revenue was $32.42 m in FY 2019

$182.8 M

APVO Mkt cap, 01-Dec-2020

$473 K

Aptevo Therapeutics Revenue Q2, 2020
Aptevo Therapeutics Net income (Q2, 2020)-6.8 M
Aptevo Therapeutics Cash, 30-Jun-20207.6 M
Aptevo Therapeutics EV178.1 M

Aptevo Therapeutics Revenue

Aptevo Therapeutics revenue was $32.42 m in FY, 2019

Embed Graph

Aptevo Therapeutics Income Statement

Aptevo Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

9.7m7.1m30.6m12.4m

Accounts Receivable

4.3m2.1m5.2m7.0m

Prepaid Expenses

5.6m6.7m6.9m4.2m

Inventories

6.6m1.0m1.8m6.1m

Current Assets

71.4m95.1m48.7m30.0m

PP&E

5.9m5.8m5.2m3.9m

Total Assets

91.9m117.0m67.5m53.4m

Accounts Payable

11.5m7.4m11.7m13.0m

Short-term debt

3.3m19.9m

Current Liabilities

19.5m18.5m17.6m38.2m

Long-term debt

18.4m15.7m19.3m3.3m

Total Debt

18.4m19.1m19.3m23.2m

Total Liabilities

41.3m35.0m37.1m41.6m

Common Stock

20.0k22.0k23.0k45.0k

Additional Paid-in Capital

151.3m155.8m157.8m179.7m

Retained Earnings

(80.7m)(73.7m)(127.4m)(167.9m)

Total Equity

50.6m82.0m30.4m11.8m

Debt to Equity Ratio

0.4 x0.2 x0.6 x

Debt to Assets Ratio

0.2 x0.2 x0.3 x

Financial Leverage

1.8 x1.4 x2.2 x4.5 x

Quarterly

USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

5.5m10.9m14.0m22.3m75.8m11.8m7.2m28.4m37.0m21.0m17.7m12.3m7.6m

Accounts Receivable

8.5m3.0m1.9m4.7m528.0k3.1m6.1m6.2m5.8m7.4m7.9m

Prepaid Expenses

3.9m3.8m6.1m5.9m6.4m4.1m4.9m5.2m6.9m5.2m2.2m1.3m641.0k

Inventories

20.1m11.6m8.1m8.0m1.2m1.3m3.0m4.0m4.3m7.0m7.5m

Current Assets

39.8m79.4m77.4m67.2m115.3m77.2m66.2m60.4m57.6m43.7m36.8m14.8m10.5m

PP&E

6.3m6.1m6.4m6.2m6.2m5.9m5.6m5.6m5.0m4.6m4.3m3.6m3.3m

Goodwill

13.9m

Total Assets

118.2m100.6m97.8m86.9m131.0m100.2m90.0m78.9m80.8m66.1m60.6m25.2m18.5m

Accounts Payable

11.2m9.0m8.8m5.3m7.5m7.3m9.5m9.8m11.0m11.9m12.1m5.0m4.7m

Short-term debt

5.3m4.2m

Current Liabilities

17.0m15.2m14.5m11.9m14.9m17.3m18.1m15.4m18.3m16.6m37.3m7.0m7.0m

Long-term debt

18.1m18.4m18.7m17.5m14.0m15.4m19.1m23.4m23.3m3.5m3.1m2.9m

Total Debt

18.1m18.4m18.7m17.5m19.3m19.6m19.1m19.4m19.6m3.5m3.1m2.9m

Total Liabilities

21.0m36.9m36.3m35.5m40.7m31.8m34.0m34.9m41.7m39.9m40.8m10.1m9.9m

Common Stock

20.0k21.0k21.0k21.0k22.0k23.0k23.0k45.0k45.0k45.0k45.0k45.0k

Additional Paid-in Capital

149.5m152.1m153.2m154.3m156.0m156.8m157.3m178.5m178.9m179.4m180.1m180.4m

Retained Earnings

(257.7m)(65.7m)(90.6m)(101.8m)(64.0m)(87.6m)(100.7m)(113.3m)(139.4m)(152.8m)(159.7m)(165.0m)(171.8m)

Total Equity

97.2m63.8m61.5m51.4m90.3m68.4m56.0m44.0m39.1m26.2m19.7m15.2m8.7m

Debt to Equity Ratio

0.3 x0.3 x0.4 x0.2 x0.3 x0.3 x0.4 x0.5 x0.7 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x0.1 x0.2 x0.2 x0.2 x0.2 x0.3 x

Financial Leverage

1.2 x1.6 x1.6 x1.7 x1.5 x1.5 x1.6 x1.8 x2.1 x2.5 x3.1 x1.7 x2.1 x

Aptevo Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(112.4m)7.0m(53.7m)(40.4m)

Depreciation and Amortization

3.4m3.1m2.4m2.2m

Accounts Receivable

2.0m(1.8m)(3.1m)(1.8m)

Inventories

13.7m(567.0k)(757.0k)(4.4m)

Accounts Payable

2.5m195.0k1.3m938.0k

Cash From Operating Activities

(36.9m)(41.6m)(51.4m)(42.4m)

Purchases of PP&E

(2.5m)(1.4m)(976.0k)(153.0k)

Cash From Investing Activities

(47.4m)29.5m72.8m4.1m

Cash From Financing Activities

89.3m9.5m(787.0k)20.1m

Net Change in Cash

5.0m(2.6m)20.6m(18.1m)

Interest Paid

537.0k1.8m1.9m

Income Taxes Paid

162.0k1.4m

Aptevo Therapeutics Ratios

USDQ2, 2016

Financial Leverage

1.2 x